达格列净联合沙库巴曲缬沙坦钠治疗射血分数降低心力衰竭的临床效果

Clinical effect of dapagliflozin combined with sacubitril valsartan sodium in the treatment of heart failure with reduced ejection fraction

目的 探讨达格列净联合沙库巴曲缬沙坦钠治疗射血分数降低心力衰竭的临床效果。方法 选取2021年3月至2022年1月收治的80例射血分数降低心力衰竭患者作为研究对象,以随机数字表法将其分为对照组和观察组,各40例。对照组采用沙库巴曲缬沙坦钠治疗,观察组在对照组基础上联合达格列净治疗。比较两组的治疗效果。结果 治疗后,观察组的游离脂肪酸(FFA)、心肌肌钙蛋白T(cTnT)、心肌肌钙蛋白I(cTnI)水平低于对照组(P<0.05)。治疗后,观察组的左心室射血分数(LVEF)高于对照组,左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)小于对照组(P<0.05)。治疗后,观察组的N末端B型脑钠肽前体(NT-proBNP)、半乳糖凝集素-3(Gal-3)水平及明尼苏达心力衰竭生活质量量表(MLHFQ)评分均低于对照组(P<0.05)。观察组的无心衰再住院生存率及无终点事件生存率高于对照组(P<0.05)。结论 达格列净联合沙库巴曲缬沙坦钠治疗射血分数降低心力衰竭患者有助于提高治疗效果,减轻心肌损伤,改善心功能,提高患者生活质量,值得推广。

Objective To investigate the clinical effect of dapagliflozin combined with sacubitril valsartan sodium in the treatment of heart failure with reduced ejection fraction.Methods A total of 80 heart failure patients with reduced ejection fraction admitted from March 2021 to January 2022 were selected as the research objects,and the patients were divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with sacubitril valsartan sodium,and the observation group was treated with dapagliflozin on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the levels of free fatty acid(FFA),cardiac troponin T(cTnT)and cardiac troponin I(cTnI)in the observation group were lower than those in the control group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)in the observation group was higher than that in the control group,and the left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD)were less than those in the control group(P<0.05).After treatment,the levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),galectin-3(Gal-3)and Minnesota Living with Heart Failure Questionnaire(MLHFQ)score in the observation group were lower than those in the control group(P<0.05).The heart failure-free rehospitalization survival rate and the end-point event-free survival rate of the observation group were higher than those of the control group(P<0.05).Conclusion Dapagliflozin combined with sacubitril valsartan sodium in the treatment of heart failure with reduced ejection fraction is helpful to improve the therapeutic effect,reduce myocardial damage,improve cardiac function and improve the quality of life of patients,which is worthy of promotion.